Anti-IGF-1R antibodies and uses thereof

Details Anti-IGF-1R antibodies and uses thereof Anti-IGF-1R antibodies and uses thereof

2007-03-28

2009-11-03

Ouspenski, Ilia (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C435S070210

Reexamination Certificate

active

07612178

ABSTRACT:
The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.

REFERENCES:
patent: 5587458 (1996-12-01), King et al.
patent: 6159730 (2000-12-01), Reff
patent: 6632927 (2003-10-01), Adair et al.
patent: 7217796 (2007-05-01), Wang
patent: 2002/0123057 (2002-09-01), Zauderer et al.
patent: 2005/0249730 (2005-11-01), Goetsch et al.
patent: 2005/0281812 (2005-12-01), Cohen et al.
patent: 2005/0288217 (2005-12-01), Clemmons et al.
patent: 2007/0059305 (2007-03-01), Wang et al.
patent: 2009/0092614 (2009-04-01), Demarest et al.
patent: 2009/0130105 (2009-05-01), Glaser et al.
patent: WO 2005/089285 (2005-09-01), None
patent: WO 2007/126876 (2007-11-01), None
patent: WO 2009/032145 (2009-03-01), None
Rudikoff et al. 1982, Proc. Natl. Acad. Sci. USA, 79: 1979-1983.
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.
Altundag, K., et al., “Insulinlike growth factor-1 receptor: predictive factor in breast cancer patients treated with trastuzumab?,”Hum. Pathol. 36:448-449, W.B. Saunders (Apr. 2005).
Baserga, R., “Oncogenes and the Strategy of Growth Factors,”Cell 79:927-930, Cell Press (1994).
Baserga, R., “The IGF-I Receptor in Cancer Research,”Exp. Cell Res. 253:1-6, Academic Press (1999).
Baserga, R., et al., “The IGF-I Receptor in Cancer Biology,”Int. J. Cancer. 107:873-877, Wiley-Liss (2003).
Baserga, R., et al., “The IGF-I receptor in cell growth, transformation and apoptosis,”Biochim. Biophys. Acta 1332:F105-F126, Elsevier Science B.V. (1997).
Beste, G., et al., “Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold,”Proc. Natl. Acad. Sci. U.S.A. 96: 1898-1903, National Academy of Sciences (1999).
Binz, H.K., et al., “High-affinity binders selected from designed ankyrin repeat protein libraries,”Nat. Biotechnol. 22:575-582, Nature America Publishing (2004).
Blakesley, V.A., et al., “Signaling via the Insulin-like Growth Factor-I Receptor: Does it Differ from Insulin Receptor Signaling,”Cytokine Growth Factor Rev. 7:153-159, Elsevier Science (1996).
Brezinsky, S.C., et al., “A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity,”J. Immunol. Methods 277:141-155, Elsevier Science (2003).
Burtrum, D., et al., “A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo,”Cancer Res. 63:8912-21(2003).
Chakravarti, A., et al., “Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinositide 3-Kinase Signaling,”Cancer Res. 62:200-207, American Association for Cancer Research (2002).
Chan, J.M., et al., “Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study,”Science 279:563-566, American Association for the Advancement of Science (1998).
Cohen, B.D., et al., “Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871,”Clin. Cancer Res. 11:2063-2073 (2005).
Davies, D. R., and Cohen, G.H., “Interactions of protein antigens with antibodies,”Proc. Natl. Acad. Sci. U.S.A. 93:7-12, National Academy of Sciences (1996).
De Meyts, P. and Whittaker, J., “Structural Biology of Insulin and IGF1 Receptors: Implications for Drug Design,”Nat. Rev. Drug Discov. 1:769-783, Nature Publishing Group (2002).
De Souza, A. T., et al., “Imprinted genes in liver carcinogenesis,”FASEB J. 11:60-67, The Federation of American Societies for Experimental Biology (1997).
Del Valle, L., et al., “Insulin-like Growth Factor I Receptor Activity in Human Medulloblastomas,”Clin. Cancer Res. 8:1822-1830, The Association (2002).
Demarest, S.J, et al., “An intermediate pH Unfolding Transition Abrogates the Ability of IgE to Interact with Its High Affinity Receptor FcεRIα,”J. Biol. Chem. 281:30755-30767, American Society for Biochemistry and Molecular Biology (Oct. 2006).
Demarest, S.J., et al., “Engineering stability into Escerichia coli secreted Fabs leads to increased functional expression,”Protein Eng. Des. Sel. 19:325-336, Oxford University Press (May 2006).
Feinberg, A.P. and Tycko, B., “The history of cancer epigenetics,”Nat. Rev. Cancer 4:143-153, Nature Publishing Group (2004).
Feng, Y., et al. , “Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function,”Mol. Cancer Ther. 5:114-120, American Association for Cancer Research, Inc. (Jan. 2006).
Furukawa, M., et al., “Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases,”Clin. Cancer Res. 11:3233-3242, The Association for Cancer Research (May 2005).
García-Echeverría, C., et al.,“In vivo anti-tumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase,”Cancer Cell 5:231-239, Cell Press (2004).
Giovannucci, E., “Nutrition, Insulin, Insulin-like Growth Factors and Cancer,”Horm. Metab. Res. 35:694-704, Georg Thieme Verlag (2003).
Goetsch, L, et al., “A Recombinant Humanized Anti-Insulin-Like Growth Factor Receptor Type I Antibody (h7C10) Enhances the Antitumor Activity of Vinorelbine and Anti-Epidermal Growth Factor Receptor Therapy Against Human Cancer Xenografts,”Int. J Cancer 113:316-328, Wiley-Liss (2005).
Hakam, A., et al., “Coexpression of IGF-1R and c-Src Proteins in Human Pancreatic Ductal Adenocarcinoma,”Dig. Dis. Sci. 48:1972-1978, Plenum Pub. Corp. (2003).
Hakam, A., et al., “Expression of Insulin-like Growth Factor-1 Receptor in Human Colorectal Cancer,”Hum. Pathol. 30:1128-1133, W.B. Saunders (1999).
Hanahan, D., and Weinberg, R.A., “The Hallmarks of Cancer,”Cell 100:57-70, Cell Press (2000).
Hankinson, S.E., et al., “Circulating concentrations of insulin-like growth factor-I and risk of breast cancer,”Lancet 351:1393-1396, Lancet Publishing Group (1998).
Hellawell, G.O., et al., “Expression of the Type 1 Insulin-like Growth Factor Receptor Is Up-Regulated in Primary Prostate Cancer and Commonly Persists in Metastatic Disease,”Cancer Res. 62:2942-2950, American Association for Cancer Research (2002).
Hey, T., et al., “Artificial, Non-antibody binding proteins for pharmaceutical and industrial applications,”TRENDS Biotechnol. 23:514-522, Elsevier Science (Oct. 2005).
Hoet, R.M., et al. ,“Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity,”Nat Biotechnol. 23:344-348, Nature America Publishing (Mar. 2005).
Jackson, J.G., et al., “Regulation of breast cancer cell motility by insulin

Affiliated with

Also associated with

Rating

Anti-IGF-1R antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-IGF-1R antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IGF-1R antibodies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4099100